Cytoreductive surgery, also known as debulking surgery, is performed to remove as much visible cancer as safely possible. It is generally considered when cancer cannot be removed through a single limited resection or when it has spread across several areas or structures.
The terms “cytoreduction” and “debulking” are often used interchangeably, although the intended extent of surgery can vary. In some cases, the goal is complete cytoreduction, meaning that no visible disease remains at the end of the operation. In others, the surgeon removes a substantial amount of the cancer while knowingly leaving disease that cannot be removed safely.
Reducing the amount of cancer may improve the effectiveness of treatments such as chemotherapy, targeted therapy, immunotherapy or radiation therapy in selected cancers. Surgery may also be used to relieve symptoms caused by the tumour, including pain, pressure, bleeding, obstruction or fluid accumulation.
Cytoreductive surgery is most commonly associated with cancers that have spread within a body cavity or across nearby organs, but it may also be considered for selected locally advanced or recurrent cancers. Its role and the definition of successful cytoreduction vary according to the cancer type.
At Apollo Cancer Centres, cytoreductive surgery is planned by a multidisciplinary team that may include surgical oncologists, medical oncologists, radiation oncologists, radiologists, pathologists, anesthetists, critical-care specialists, nutritionists and rehabilitation teams. The expected benefit of removing the cancer is carefully balanced against the complexity and risks of surgery.
- Have cancer involving multiple areas that may still be surgically removable
- Have locally advanced cancer involving nearby tissues or organs
- Have cancer that has spread within the abdominal, pelvic or another body cavity
- Have selected recurrent cancer that remains amenable to surgical removal
- Have symptoms such as pain, pressure, bleeding or obstruction that may improve after reducing the tumour burden
- May benefit from reducing the amount of cancer before or after systemic treatment
- Have disease for which the amount of residual tumour after surgery is known to influence treatment outcomes
- Have responded to chemotherapy, targeted therapy, immunotherapy or radiation therapy and may now be suitable for surgery
- Are medically fit to undergo what may be a long and complex operation
- Are expected to receive a meaningful clinical benefit that justifies the risks and recovery involved
How the Procedure is Performed
Before the Procedure
Before cytoreductive or debulking surgery:
The surgical team reviews the biopsy, imaging scans, previous treatments, laboratory results, medical history and current medications.
Detailed imaging may be performed to map the distribution of cancer and assess its relationship to organs, blood vessels and other important structures.
In selected cases, a diagnostic laparoscopy or another procedure may be used to assess whether meaningful cytoreduction is likely to be achievable.
The case is reviewed by a multidisciplinary tumour board to determine whether surgery should be performed before systemic treatment, after an initial course of treatment or primarily to relieve symptoms.
The patient’s fitness for major surgery and anesthesia is assessed. This may include blood tests, heart and lung evaluation, nutritional assessment and consultation with an anesthetist.
The surgeon explains the goal of the operation, including whether complete removal of visible disease is considered possible or whether the intention is to reduce the tumour burden.
The possible need to remove parts of affected organs or nearby structures is discussed.
The team explains whether bowel resection, removal of other involved organs, reconstruction, blood transfusion or a temporary or permanent stoma may be required.
Where relevant, the possibility of combining surgery with a specialised treatment such as heated intraperitoneal chemotherapy is discussed separately. This is not required or appropriate for every patient undergoing cytoreduction.
Nutritional support, physical conditioning and optimisation of existing medical conditions may be recommended before surgery.
Instructions are provided about fasting, medications, bowel preparation where required, smoking cessation and admission to the hospital.
During the Procedure
Cytoreductive surgery is usually performed under general anesthesia.
Most extensive cytoreductive procedures are performed through an open incision, although a minimally invasive approach may be considered in selected cases with limited disease.
The surgeon carefully examines the affected area to assess the distribution and extent of the cancer.
Visible tumours are removed from the involved tissues and organs wherever this can be done safely.
Depending on the extent of disease, surgery may involve removing part or all of one or more affected organs or structures.
Sections of the bowel, urinary tract, reproductive organs, lining of the abdominal cavity, diaphragm, spleen, liver surface or other involved tissues may need to be removed in selected abdominal or pelvic procedures.
Bowel or other hollow organs may be reconnected after the affected section is removed. A temporary or permanent stoma may occasionally be required.
Nearby lymph nodes may be sampled or removed when required for cancer staging or treatment.
In selected cases, a pathologist may examine tissue during the operation to clarify the diagnosis or assess a suspicious area.
Reconstruction may be performed to restore continuity or function after the removal of involved tissue.
Drains, tubes or feeding access may be placed to support recovery.
The surgeon records the extent of disease found and the amount of tumour remaining at the end of the procedure.
All removed tissue is sent for detailed histopathological examination.
Cytoreductive surgery may take several hours, particularly when cancer involves multiple areas or organs. The duration depends on the extent of disease, the procedures required and whether reconstruction or another specialised treatment is performed during the same operation.
After the Procedure
Recovery: Recovery depends on the extent of cytoreduction, the number and type of organs involved, the patient’s overall health and whether reconstruction or an additional treatment has been performed.
Hospital Stay: Patients undergoing major cytoreductive surgery may remain in hospital for several days or longer. Some may initially require monitoring in a high-dependency or intensive care unit.
Pain Management: Pain is managed using a personalised combination of medicines and, when appropriate, an epidural, nerve block or other regional pain-relief technique.
Nutrition: Fluids and food are restarted according to the operation and the return of bowel and other organ functions. Intravenous nutrition, tube feeding or specialised dietary support may occasionally be required.
Mobility and Breathing Exercises: Patients are encouraged to perform breathing exercises, sit up and begin walking as soon as it is safe. Early movement helps reduce the risk of chest infections, muscle loss and blood clots.
Organ Function Monitoring: The care team monitors bowel, bladder, kidney, liver, lung and cardiovascular function according to the procedures performed.
Wound, Drain and Stoma Care: Patients and caregivers receive guidance about caring for the incision and any drains, tubes or stoma.
Histopathology Review: The final report provides information about the cancer type, the tissues and organs involved, lymph-node findings and other features that guide further treatment.
Further Cancer Treatment: Chemotherapy, targeted therapy, immunotherapy, hormonal therapy or radiation therapy may be recommended after recovery. Surgery is often one part of a combined treatment plan.
Resuming Routine: Recovery after extensive cytoreduction may take several weeks or months. Return to work, driving, exercise and normal activities should follow individual medical advice.
Follow-up Care: Follow-up appointments assess wound healing, nutritional recovery, organ function and the next stage of cancer treatment.
Key Advantages
- Fever, chills or increasing weakness
- Worsening pain that is not controlled by prescribed medication
- Increasing redness, warmth, swelling, discharge or bleeding from the incision
- Persistent vomiting, increasing abdominal swelling or inability to eat or drink
- Failure to pass urine, gas or stool as advised by the surgical team
- New or worsening diarrhoea, constipation or an unexpected change in bowel function
- Shortness of breath, chest pain or coughing up blood
- New swelling or pain in a leg
- Reduced urine output or a marked change in urine
- A problem with a drain, feeding tube, urinary tube or stoma
- Sudden weakness, dizziness, confusion or fainting
- Any symptom identified by the surgical team as specific to the procedure
Continuum of Care
Cytoreductive or debulking surgery is usually part of a coordinated cancer-treatment pathway. After surgery, patients may receive:
